Related Experiment Video
Updated: May 4, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Theranostics in Neuroendocrine Tumors.
Nadine Mallak1, Sophia R O'Brien2, Daniel A Pryma2
1From the Department of Diagnostic Radiology, Oregon Health & Sciences University, Portland, OR.
This review explores advancements in somatostatin receptor (SSTR)-targeted imaging and therapy for neuroendocrine tumors (NETs). It also discusses norepinephrine transporter-targeted therapy for pheochromocytomas/paragangliomas (PPGLs), noting recent changes in treatment availability.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmacology
Background:
- Neuroendocrine tumors (NETs) and pheochromocytomas/paragangliomas (PPGLs) are rare neoplasms originating from neuroendocrine cells.
- Gastroenteropancreatic NETs frequently overexpress somatostatin receptors (SSTRs), while PPGLs typically overexpress the norepinephrine transporter.
- Recent advancements have significantly impacted the diagnostic and therapeutic strategies for these rare tumors.
Purpose of the Study:
- To provide a comprehensive review of current SSTR-targeted imaging and therapy for NETs.
- To discuss the role and outcomes of norepinephrine transporter-targeted therapy for PPGLs.
- To explore the evolving landscape of theranostics for both NETs and PPGLs, including recent treatment availability changes.
Main Methods:
- Review of Food and Drug Administration-approved SSTR-agonist positron emission tomography tracers.
- Analysis of predictive imaging biomarkers for SSTR-targeted therapies.
- Discussion of 177Lu-DOTATATE peptide receptor radionuclide therapy, including retreatment and posttherapy imaging.
- Examination of 131I-metaiodobenzylguanidine (mIBG) theranostics for PPGLs and the implications of its commercial unavailability.
Main Results:
- SSTR-targeted imaging and treatment have revolutionized NET management.
- 177Lu-DOTATATE offers a significant therapeutic option for NETs, with evolving practices in retreatment and imaging.
- Norepinephrine transporter-targeted therapy with 131I-mIBG has shown the best outcomes for PPGLs, though its availability is now limited.
- SSTR theranostics are being explored as an alternative for PPGLs.
Conclusions:
- SSTR-targeted theranostics represent a cornerstone in modern NET management.
- While 131I-mIBG was a key therapy for PPGLs, its unavailability necessitates exploring alternative strategies like SSTR theranostics.
- Continued research and development in theranostic approaches are crucial for improving outcomes in patients with NETs and PPGLs.
More Related Videos
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists